BioXell to cut jobs as it terminates Elocalcitol development

Published: 29-Apr-2009
Media Regulatory

BioXell, an Italian biopharmaceutical company, is to cut 14 jobs following its decision to terminate its clinical development activities for Elocalcitol in the indications OAB and Benign Prostatic Hyperplasia.


BioXell, an Italian biopharmaceutical company, is to cut 14 jobs following its decision to terminate its clinical development activities for Elocalcitol in the indications OAB and Benign Prostatic Hyperplasia.

The company has already suspended the Phase II trial of Elocalcitol in Male Infertility as well as putting on hold the initiation of the Phase I study of BXL746 in the prevention of post-surgical adhesions. All research activities with regards to the company's Vitamin D3 and TREM technologies will also be terminated.

BioXell intends to focus its future development efforts on the progression of its monoclonal antibody BXL1H5 for the treatment of chronic pain. The antibody, still in preclinical development, is expected to enter the clinical phase in the first half of 2011.

Dr Francesco Sinigaglia will step down as chief executive but remain as md until the shareholders" meeting on 30 April. Thereafter he will continue providing his services to the company as a consultant.

Niels Ackermann, BioXell's current chief financial officer, will take over as chief executive with immediate effect.

Sinigaglia said: "At a time when BioXell is reviewing its strategic options, I think it is the right time to step down after more than seven years as the founding ceo. I have enormous confidence in our employees and management. My overriding priority is to ensure the smooth transition in the best interest of the company."

Professor Thomas Szucs, chairman of the board of directors of BioXell, thanked Sinigaglia for his "significant contribution and leadership" and wished him ongoing success for his future endeavours.

BioXell was founded in 2002 as a spin-out from Roche. It currently employs 39 people in Milan.

See more

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Read more
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now